| pubmed-article:21444918 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C0003316 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C0054946 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C0444626 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C0233820 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C1853126 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C1417326 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C1706319 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:21444918 | lifeskim:mentions | umls-concept:C1999230 | lld:lifeskim |
| pubmed-article:21444918 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21444918 | pubmed:dateCreated | 2011-7-15 | lld:pubmed |
| pubmed-article:21444918 | pubmed:abstractText | CD20 is a cell-surface marker of normal and malignant B cells. Rituximab, a monoclonal antibody targeting CD20, has improved the treatment of malignant lymphomas. Therapeutic CD20 antibodies are classified as either type I or II based on different mechanisms of killing malignant B cells. To reveal the molecular basis of this distinction, we fine-mapped the epitopes recognized by both types. We also determined the first X-ray structure of a type II antibody by crystallizing the obinutuzumab (GA101) Fab fragment alone and in complex with a CD20 cyclopeptide. Despite recognizing an overlapping epitope, GA101 binds CD20 in a completely different orientation than type I antibodies. Moreover, the elbow angle of GA101 is almost 30° wider than in type I antibodies, potentially resulting in different spatial arrangements of 2 CD20 molecules bound to a single GA101 or rituximab molecule. Using protein tomography, different CD20 complexes were found to be associated with the 2 antibodies, and confocal microscopy showed different membrane compartmentalization of these subpopulations of the cellular CD20 pool. Our findings offer a possible molecular explanation for the different cellular responses elicited by type I and II antibodies. | lld:pubmed |
| pubmed-article:21444918 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21444918 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21444918 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21444918 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21444918 | pubmed:issn | 1528-0020 | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:FrankeAndreas... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:KleinChristia... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:BrännströmAnn... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:MundiglOlafO | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:TimmermanPete... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:SchaeferWolfg... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:HopfnerKarl-P... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:SchwaigerManf... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:SlootstraJerr... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:Niederfellner... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:MössnerEkkeha... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:LammensAlfred... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:JeneweinStefa... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:UmanaPabloP | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:GeorgesGuy... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:WiechmannKorn... | lld:pubmed |
| pubmed-article:21444918 | pubmed:author | pubmed-author:LindstromFrid... | lld:pubmed |
| pubmed-article:21444918 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21444918 | pubmed:day | 14 | lld:pubmed |
| pubmed-article:21444918 | pubmed:volume | 118 | lld:pubmed |
| pubmed-article:21444918 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21444918 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21444918 | pubmed:pagination | 358-67 | lld:pubmed |
| pubmed-article:21444918 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:meshHeading | pubmed-meshheading:21444918... | lld:pubmed |
| pubmed-article:21444918 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21444918 | pubmed:articleTitle | Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. | lld:pubmed |
| pubmed-article:21444918 | pubmed:affiliation | Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany. | lld:pubmed |
| pubmed-article:21444918 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21444918 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:931 | entrezgene:pubmed | pubmed-article:21444918 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21444918 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21444918 | lld:pubmed |
